Triple-negative breast cancer: role of antiangiogenic agents
- PMID: 20164688
- DOI: 10.1097/PPO.0b013e3181d38514
Triple-negative breast cancer: role of antiangiogenic agents
Abstract
New blood vessel formation plays an important role in breast cancer growth, invasion, and metastasis. Tumor growth is preceded by the development of new blood vessels, which provide a pathway for metastases and nutrients essential for growth. Vascular endothelial growth factor (VEGF) is a key angiogenic mediator that stimulates endothelial cell proliferation and regulates vascular permeability. Highly proliferative tumors, such as those that are negative for the estrogen, progesterone, and HER2/neu receptors have enhanced angiogenesis that supports rapid growth and early metastases and have been found to have high levels of VEGF. Drugs developed to inhibit the angiogenic process may be particularly effective in triple-negative breast cancer. Subset analyses have demonstrated efficacy with combinations of the VEGF antibody bevacizumab in combination with chemotherapy and, to a limited degree, with other antiangiogenic agents. Many targeted biologic agents in development inhibit angiogenesis including those that inhibit the mammalian target of rapamycin, fibroblast growth factor, Notch, hypoxic inducible factor, 2-methoxyestradiol, insulin like growth factor, matrix metalloproteinase, and others. Ongoing studies are focusing on the effects of these agents in triple-negative disease, and there is an urgent need to identify markers that can predict response to specific targeted therapy.
Similar articles
-
Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.Clin Cancer Res. 2003 Nov 1;9(14):5313-7. Clin Cancer Res. 2003. PMID: 14614015
-
Antiangiogenic strategies, compounds, and early clinical results in breast cancer.Crit Rev Oncol Hematol. 2004 Feb;49(2):91-107. doi: 10.1016/S1040-8428(03)00168-9. Crit Rev Oncol Hematol. 2004. PMID: 15012971 Review.
-
Directed therapy of subtypes of triple-negative breast cancer.Oncologist. 2011;16 Suppl 1:71-8. doi: 10.1634/theoncologist.2011-S1-71. Oncologist. 2011. PMID: 21278443
-
Therapeutic strategies for triple-negative breast cancer.Cancer J. 2008 Nov-Dec;14(6):343-51. doi: 10.1097/PPO.0b013e31818d839b. Cancer J. 2008. PMID: 19060597 Review.
-
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.Integr Cancer Ther. 2005 Dec;4(4):315-21. doi: 10.1177/1534735405282557. Integr Cancer Ther. 2005. PMID: 16282508 Review.
Cited by
-
Angiogenesis and breast cancer.J Oncol. 2010;2010:576384. doi: 10.1155/2010/576384. Epub 2010 Oct 7. J Oncol. 2010. PMID: 20953378 Free PMC article.
-
Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.PLoS One. 2016 Aug 31;11(8):e0160148. doi: 10.1371/journal.pone.0160148. eCollection 2016. PLoS One. 2016. PMID: 27579484 Free PMC article. Review.
-
Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.Virchows Arch. 2012 Jul;461(1):33-9. doi: 10.1007/s00428-012-1252-9. Epub 2012 Jun 15. Virchows Arch. 2012. PMID: 22699808
-
Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.Eur Radiol. 2016 May;26(5):1474-84. doi: 10.1007/s00330-015-3948-0. Epub 2015 Aug 27. Eur Radiol. 2016. PMID: 26310583
-
Effects of melatonin on HIF-1α and VEGF expression and on the invasive properties of hepatocarcinoma cells.Oncol Lett. 2016 Jul;12(1):231-237. doi: 10.3892/ol.2016.4605. Epub 2016 May 18. Oncol Lett. 2016. PMID: 27347130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous